gefitinib
1 clinical trial
13 products
25 abstracts
1 indication
1 target
Indication
Bladder CancerTarget
EGFR mutationAbstract
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).Org: Next Oncology Virginia and Virginia Cancer Specialists, Henry Ford Cancer Institute, Detroit, MI, UC Davis Comprehensive Cancer Center, Department of Medical Oncology, Harbin Medical University Cancer Hospital, Henan Cancer Hospital,
Abstract
Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study.Org: Huadong Medicine Co., Ltd, Huadong Global Development Center, HangZhou ZhongMei HuaDong Pharmaceutical Company,
Abstract
A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation–positive non-small cell lung cancer (OPEN/TORG2040).Org: Kitasato Univeristy Hospital, Sagamihara-Shi, Japan, Toho University Omori Medical Center, Tokyo, Japan, Division of Respirology Neurology and Rheumatology Department of Internal Medicine, Kurume University Hospital, Kurume, Japan, Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan, Tochigi Cancer Center, Utsunomiya, Japan,
Abstract
Phase Ib clinical study of first-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous non-small cell lung cancer with EGFR mutation.Org: Tianjin Medical University Cancer Institute and Hospital, Tianjin, China,
Abstract
Evaluating generalizability of landmark randomized controlled trials in common metastatic cancers using machine learning-based emulated trials.Org: Navajo Indian Health Service,
Abstract
Cutaneous adverse event profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer: A meta-analysis of phase 3 randomized controlled trials.Org: Mount Sinai Beth Israel, Mount Sinai Hospital-Breast Medical Oncology, Kyoto University Hospital, Center for Thoracic Oncology, Tisch Cancer Institute,
Clinical trial
A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the BladderStatus: Terminated, Estimated PCD: 2012-01-06
Abstract
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.Org: Guangdong Lung Cancer Institute, China National Biotec Group, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou JOYO Pharma, Cancer Hospital,
Abstract
MicroOrganoSpheres as a clinically applicable precision oncology platform for the discovery of novel therapies in colorectal cancer.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Medical Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center,
Abstract
A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study.Org: Department of Hematology and Clinical Oncology, Shinshu University School of Medicine, Matsumoto-Shi, Japan, Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Mibu, Japan, Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan,
Abstract
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Nashville, TN, EQRx, Cambridge, MA,
Abstract
Predictive value of co-existing genetic alterations and tumor mutation burden for patients with completely resected non-small cell lung cancer harboring EGFR mutation: Biomarker analysis of phase III IMPACT study.Org: Kanagawa Cardiovascular and Respiratory Center, National Cancer Center Hospital East, Kashiwa, Japan, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Department of Data Sciences, Internal Medicine III, Wakayama Medical University,
Abstract
AX-0085, a novel AXL kinase inhibitor, and effects on osimertinib-resistance in non–small-cell lung cancer.Org: Axceso Biopharma Co., Ltd., College of Medicine, Hanyang University, Department of Life Science, Ewha Research Center for Systems Biology, Ewha Womans University,
Abstract
Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).Org: Yonsei Cancer Center, Yonsei University Health System, Korea University Anam Hospital, Division of Medical Oncology, Gachon University Gil Medical Center, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Department of Internal Medicine, Division of Hematology and Medical Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine,
Abstract
Circulating tumor DNA to guide furmonertinib monotherapy or combination therapy in advanced EGFR mutant non-small cell lung cancer (NSCLC): A randomized, open-label, multicenter study (FOCUS-C).Org: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Affiliated Dongguan Hospital,
Abstract
A comparative study evaluating the quality of life in patients receiving chemotherapy versus oral TKI in the third line and beyond setting for advanced non–small-cell lung cancer.Org: Tata Memorial Centre, Tata Memorial Hospital (HBNI),
Abstract
Clinical efficacy analysis of furmonertinib and structural insights into sensitivity to diverse TKIs for NSCLC with EGFR exon 20 insertion.Org: Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhoukou Central Hospital, Zhumadian Central Hospital,
Abstract
Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University Hospital of Cologne, China Medical University Hospital, Bhaktivedanta Hospital And Research Centre and School of Consciouness,
Abstract
Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study.Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Harbin Medical University Cancer Hospital, Xuzhou Central Hospital, Xuzhou, China, The First Hospital of China Medical University, Shenyang, China,
Abstract
Retrospective evaluation of erlotinib and gefitinib used in the military health system from the perspective of drug-drug interactions.Org: Walter Reed National Military Medical Center, Fort Belvoir Community Hospital,
Abstract
Efficacy and safety study of osimertinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation.Org: Hospital Juan Ramón Jiménez, Hospital Juan Ramón Jimenez,
Abstract
Retreatment with EGFR inhibitor in non-small cell lung cancer patients previously exposed to EGFR-TKI: A systematic review and meta-analysis.Org: Catholic University of Pelotas, Princess Margaret Hospital, Universidade de Brasília, Centro de Oncologia do Parana, Universidade Estadual do Centro Oeste - UNICENTRO, Guarapuava, Brazil,
Abstract
Relationship between EGFR inhibition in lung adenocarcinoma, cell surface expression of the placental antigen ALPP, and efficacy of ALPP-ADC therapy.Org: University of Texas at MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, KoBioLabs, Inc., MSD R&D, Co., Ltd, University of Texas MD Anderson Cancer Center,
Abstract
Differential efficacy of tyrosine kinase inhibitors (TKIs) according to the types of EGFR mutations and agents in non-small cell lung cancer (NSCLC): A real-world study.Org: Ajou University School of Medicine, Department of Hematology-Oncology, Ajou University Hospital,
Abstract
An individual patient-level meta-analysis of non–small-cell lung cancer leptomeningeal metastases treated with epidermal growth factor receptor inhibitors.Org: McGill University Health Center, The Second Affiliated Hospital Of Nanchang University, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Mayo Clinic, Memorial Sloan Kettering Cancer Center,
Product
gefitinib or erlotinibProduct
gefitinib or osimertinib, followed by cisplatin and pemetrexed, then gefitinib or osimertinibProduct
EGFR TKIsProduct
targeted therapiesProduct
gefitinib + placeboProduct
EGFR-TKIProduct
gefitinib/erlotinibProduct
gefitinib + bevacizumabProduct
EGFR TKIProduct
EGFR-TKI monotherapyProduct
gefitinib or osimertinib